Calcium Folinate — Drug Intelligence | 74 EU Trials

Filter these 74 trials by condition, phase, country and more.

Open in Search →

74 Registered trials

40 Recruiting

25 Completed trials

54 Sponsors

23 Countries

Phase III

Phase II

Phase I/II

Phase III: 25 Phase II/III: 4 Phase II: 29 Phase I/II: 9 Phase III/IV: 1 Phase IV: 3 Phase I (Other): 1 Phase I (FiH): 2

Oversight events:

3 serious breaches 2 temporary halts 3 unexpected events 10 corrective measures across 9 trials

View oversight register →

Indications tested

Colorectal cancer metastatic 5 Colorectal cancer 4 Non-small cell lung cancer 3 Adenocarcinoma gastric 2 Adenocarcinoma pancreas 2 Ductal adenocarcinoma of pancreas 1 Mesothelioma 1 Oesophageal adenocarcinoma 1 Thymoma 1 Breast cancer metastatic 1 Gastrooesophageal cancer 1 Non-small cell lung cancer metastatic 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 7 Fondazione GONO G.I. 4 Arcus Biosciences Inc. 3 Assistance Publique Hopitaux De Paris 3 Bristol-Myers Squibb Services Unlimited Company 3 Amgen Inc. 2 AstraZeneca AB 2 Centre Hospitalier Universitaire De Bordeaux 2 Pfizer Inc. 2 Unicancer 2 Ability Pharmaceuticals S.A. 1 Alligator Bioscience AB 1

All trials

74 total

PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic co… Not authorised

2024-519922-19-00 Phase II 1 country Hospices Civils De Lyon
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke… Pending

2024-514682-19-00 Phase III 2 countries Universitaetsklinikum Heidelberg AöR
Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer (The DUREC trial) Pending

2024-515240-24-00 Phase II 1 country Grupo Espanol Multidisciplinar En Cancer Digestivo
Efficiency of a composite personalised care on functional outcome in early psychosis: A Prospective Randomised Controlled Trial Pending

2025-520573-39-00 Phase IV 1 country Groupe Hospitalier Universitaire Paris Psychiatrie Et Neuroscience
Impact of Biweekly and Triweekly Dosing Regimens Pending

2025-522305-38-00 Phase II 1 country University Of Pecs
Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer Pending

2025-522431-34-00 Phase II 1 country Region Hovedstaden
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorect… Pending

2025-523521-18-00 Phase III 8 countries Pfizer Inc.
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat… Pending

2025-523735-19-00 Phase III 10 countries Incyte Corp.
LuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and… Recruiting

2023-508995-12-01 Phase II 4 countries Novartis Pharma AG
Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting

2024-517700-12-00 Phase III 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Sotorasib combined with first-line chemotherapy for advanced pancreatic adenocarcinoma Recruiting

2024-516233-12-00 Phase I (Other) 2 countries Asociacion Grupo Tratamiento De Tumores Digestivos
BreAK CRC (001) trial Recruiting

2024-512011-45-00 Phase I (FiH) 2 countries Brenus Pharma
Beamion BCGC-1: A study to find a suitable dose of zongertinib used alone and in combination with other treatments to test whether it helps … Recruiting

2023-509566-38-00 Phase I/II 5 countries Boehringer Ingelheim International GmbH
Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Previously Untreated Advanced or Me… Recruiting

2025-523263-37-00 Phase II/III 6 countries Bristol-Myers Squibb Services Unlimited Company
Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Previously Untreated, Unresectable, or Met… Recruiting

2025-523224-45-00 Phase II/III 11 countries Bristol-Myers Squibb Services Unlimited Company
Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervou… Recruiting

2025-521144-38-00 Phase II 2 countries Bristol-Myers Squibb Services Unlimited Company
A study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo®, in combination with mFOLFOX6 and bevacizumab versus… Recruiting

2024-519590-19-00 Phase II 3 countries Ono Pharmaceutical Co. Ltd.
Phase Ib-II, non-randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with modFOLFIRINOX for front-line trea… Recruiting

2024-511459-16-00 Phase I/II 1 country Clinica Universidad De Navarra
Using lab-grown mini-tumors from pancreatic cancer tissue to predict and improve post-surgery treatment for pancreatic cancer Recruiting

2023-510490-34-00 Phase II 1 country Universitaetsklinikum Ulm AöR
A clinical study of MK-1084 with targeted therapy and chemotherapy in people with colorectal cancer (MK-1084-012). Recruiting

2024-517232-22-00 Phase III 9 countries Merck Sharp & Dohme LLC
A clinical study of ifinatamab deruxtecan and pembrolizumab with or without chemotherapy in people with esophageal cancer (MK-3475-06E) Recruiting

2024-514273-22-00 Phase I/II 5 countries Merck Sharp & Dohme LLC
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Phase II 1 country Unicancer
metastatic colorectal cancer Recruiting

2023-504831-42-00 Phase III 1 country Assistance Publique Hopitaux De Paris
Master Protocol of Novel Study Interventions and Combinations in Participants with Colorectal Cancer Recruiting

2024-518469-84-00 Phase II 5 countries AstraZeneca AB

Showing 1–24 of 74 trials

← All drugs A–Z